Novartis' core earnings per share for the fourth quarter were $1.98, estimated at $1.82.
Core operating profit for the fourth quarter was $4.86 billion, estimated at $4.44 billion.
Core net profit for the fourth quarter was $3.93 billion, estimated at $3.61 billion.
Net sales for the fourth quarter were $13.15 billion, estimated at $12.88 billion.
Sales of Cosentyx for the fourth quarter were $1.60 billion, estimated at $1.67 billion.
Sales of Entresto for the fourth quarter were $2.18 billion, estimated at $2.03 billion
